CTOs on the Move


 
Get hassle-free reproductive care for Herpes, BV, Yeast, UTI, Primary Care & Contraception. Same-day prescriptions picked up locally in a few hours or delivered FREE, discreetly packaged, to your home.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.hellowisp.com
  • 548, Market Street
    San Francisco, CA USA 94104
  • Phone: 415.209.5810

Executives

Name Title Contact Details

Similar Companies

Motion Picture and Television Fund

MPTF supports our entertainment community in living and aging well, with dignity and purpose, and in helping each other in times of need.

Valify

Drive tangible savings to your bottom line in weeks versus months using Valify, the only SaaS analytics and benchmarking tool for Purchased Services. Leave manual data aggregation behind. Automate the discovery of opportunity and begin tracking performance so your team can focus on realizing savings.

BioCare

BioCare, Inc. is comprised of BioCareSD, a leading national specialty distributor of life-saving therapies, CanyonCareRX, a full-service specialty pharmacy, and LogiCare3PL, a national provider of time- and temperature-sensitive pharmaceutical logistics services. Headquartered in Tempe, Arizona, BioCare, Inc. has been devoted to delivering specialty and therapeutic biological products since 1982.

ONYX Healthcare USA

ONYX Healthcare USA is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.